HIF1A and breast cancer: Research indicates that HIF-1α may contribute to resistance against conventional therapies via various signaling pathways, including drug efflux, tumor stem cell enrichment, autophagy, and apoptosis (192, 195), necessitating further investigation into HIF-1α-induced drug resistance mechanisms in BC.